Sean Sheridan

Vice President
Sean Sheridan_Litigation_Life Sciences_Damages_Charles River Associates

Dr. Sean Sheridan is Vice President in the Life Sciences Practice at CRA. He has served as an expert witness in cases brought before federal and state courts, the Patent Trial and Appeal Board, the International Trade Commission, and arbitration tribunals.

Dr. Sheridan has developed numerous damages analyses related to patent infringement, breach of contract, and trade secret misappropriation, including analyses quantifying lost profits, reasonable royalties, and unjust enrichment. He has also provided financial consulting services for a variety of non-litigation purposes including transaction due diligence, license negotiations, and strategic decision‐making. The engagements he has worked on span a wide range of industries and products, including pharmaceuticals, recombinant therapeutic proteins, vaccines, gene editing, medical devices, diagnostics, research tools, electronic health records, and many others outside of the life sciences.

Previously, Dr. Sheridan was as an assistant director at the technology transfer office at the University of Chicago where he was responsible for managing the intellectual property strategy for a broad range of technologies and was frequently required to assess the value of new discoveries and potential products. In that role he personally negotiated a variety of contracts including licenses, option agreements, and collaboration agreements with companies ranging from Fortune 500 firms to small start-ups.

Dr. Sheridan is a frequent speaker and instructor on intellectual property valuation, and also publishes on related topics. He was named to the IAM Patent 1000: The World’s Leading Patent Professionals (economic experts) every year since 2019.

Selected Engagements

  • 01
    AAA dispute involving the breach of a contract between biopharmaceutical companies engaged in the development of monoclonal antibody therapeutics
    In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two biopharmaceutical companies, CRA...
    View engagement
  • 02
    Determination of appropriate intercompany royalty rate for genomic profiling kit
    CRA was retained by a pharmaceutical and diagnostic company to determine an appropriate intercompany royalty rate to be paid between affiliate companies for...
    View engagement
  • 03
    Evaluation of a diabetes treatment
    CRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to...
    View engagement